[{"id":"2d640cff-e8d0-459a-ae6a-92adad2804d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03173950","created_at":"2022-04-11T23:54:29.961Z","updated_at":"2025-02-25T14:07:01.366Z","phase":"Phase 2","brief_title":"Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers","source_id_and_acronym":"NCT03173950","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCOR • FOXR2","pipe":"","alterations":" ","tags":["BCOR • FOXR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 07/13/2017","start_date":" 07/13/2017","primary_txt":" Primary completion: 07/15/2025","primary_completion_date":" 07/15/2025","study_txt":" Completion: 07/15/2026","study_completion_date":" 07/15/2026","last_update_posted":"2025-02-18"},{"id":"fa25f52e-d775-44da-9710-a28c3fa442b5","acronym":"MIRAGE","url":"https://clinicaltrials.gov/study/NCT06275919","created_at":"2024-02-23T18:27:39.333Z","updated_at":"2025-02-25T15:14:15.952Z","phase":"Phase 2","brief_title":"Regorafenib for Recurrent Grade 2 and 3 Meningioma (MIRAGE Trial)","source_id_and_acronym":"NCT06275919 - MIRAGE","lead_sponsor":"Istituto Oncologico Veneto IRCCS","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 09/23/2024","start_date":" 09/23/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2025-02-13"},{"id":"f4599b74-514d-415f-a4c1-0ad32a88ef07","acronym":"A071401","url":"https://clinicaltrials.gov/study/NCT02523014","created_at":"2021-01-18T12:11:52.655Z","updated_at":"2025-02-25T13:11:46.229Z","phase":"Phase 2","brief_title":"Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas","source_id_and_acronym":"NCT02523014 - A071401","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • NF2 • SMO • CDK6 • CCND2 • CCND3","pipe":" | ","alterations":" PIK3CA mutation • PTEN mutation","tags":["PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • NF2 • SMO • CDK6 • CCND2 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Truqap (capivasertib) • Erivedge (vismodegib) • GSK2256098"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 09/28/2015","start_date":" 09/28/2015","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-01-15"},{"id":"10e7c484-a234-4aa3-b3ff-69b3ed1da252","acronym":"CA209-324","url":"https://clinicaltrials.gov/study/NCT02648997","created_at":"2024-01-24T15:18:16.455Z","updated_at":"2025-02-25T14:36:04.275Z","phase":"Phase 2","brief_title":"An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma","source_id_and_acronym":"NCT02648997 - CA209-324","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" PD-L1 • PD-1 • IL2RA • CD4 • CD69 • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1 • IL2RA • CD4 • CD69 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-12-19"},{"id":"b02d7446-9c2e-44de-aefb-87c2ab738292","acronym":"DOMINO START","url":"https://clinicaltrials.gov/study/NCT04081701","created_at":"2021-01-18T19:59:05.539Z","updated_at":"2025-02-25T15:43:40.367Z","phase":"Phase 4","brief_title":"68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.","source_id_and_acronym":"NCT04081701 - DOMINO START","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" SSTR • SSTR2","pipe":" | ","alterations":" SSTR positive","tags":["SSTR • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/04/2019","start_date":" 09/04/2019","primary_txt":" Primary completion: 12/31/2038","primary_completion_date":" 12/31/2038","study_txt":" Completion: 12/31/2038","study_completion_date":" 12/31/2038","last_update_posted":"2024-12-19"},{"id":"002e6ccc-3a81-4cfa-b237-64f0c73db083","acronym":"INTUITT-NF2","url":"https://clinicaltrials.gov/study/NCT04374305","created_at":"2021-01-18T21:07:59.980Z","updated_at":"2025-02-25T14:51:47.217Z","phase":"Phase 2","brief_title":"Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)","source_id_and_acronym":"NCT04374305 - INTUITT-NF2","lead_sponsor":"Scott R. Plotkin, MD, PhD","biomarkers":" NF2","pipe":"","alterations":" ","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • Alunbrig (brigatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/20/2020","start_date":" 06/20/2020","primary_txt":" Primary completion: 12/01/2029","primary_completion_date":" 12/01/2029","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2024-11-18"},{"id":"243bbd2b-9fa8-4a47-8997-af40c6654b26","acronym":"SEL-TH-1601","url":"https://clinicaltrials.gov/study/NCT03095248","created_at":"2021-01-18T15:15:00.040Z","updated_at":"2025-02-25T14:57:54.989Z","phase":"Phase 2","brief_title":"Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors","source_id_and_acronym":"NCT03095248 - SEL-TH-1601","lead_sponsor":"Children's Hospital Medical Center, Cincinnati","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 05/08/2017","start_date":" 05/08/2017","primary_txt":" Primary completion: 05/21/2024","primary_completion_date":" 05/21/2024","study_txt":" Completion: 05/21/2024","study_completion_date":" 05/21/2024","last_update_posted":"2024-10-04"},{"id":"69c0c3d7-d12e-4846-a87b-98d5f38f2dcd","acronym":"SJDAWN","url":"https://clinicaltrials.gov/study/NCT03434262","created_at":"2021-01-18T16:56:26.116Z","updated_at":"2025-02-25T15:54:00.489Z","phase":"Phase 1","brief_title":"SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors","source_id_and_acronym":"NCT03434262 - SJDAWN","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • gemcitabine • Kisqali (ribociclib) • Odomzo (sonidegib) • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 03/05/2018","start_date":" 03/05/2018","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 05/24/2024","study_completion_date":" 05/24/2024","last_update_posted":"2024-05-31"},{"id":"ed745a1a-e25b-481e-9a43-45f739d28d5a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04239092","created_at":"2021-01-18T20:36:34.133Z","updated_at":"2024-07-02T16:35:03.671Z","phase":"Phase 1","brief_title":"9-ING-41 in Pediatric Patients With Refractory Malignancies.","source_id_and_acronym":"NCT04239092","lead_sponsor":"Actuate Therapeutics Inc.","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • cyclophosphamide • irinotecan • topotecan • elraglusib (9-ING-41) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 06/05/2020","start_date":" 06/05/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-05-15"},{"id":"fca0acc3-ee52-4102-a447-7fd22d0a32ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT02162732","created_at":"2021-01-18T10:04:10.523Z","updated_at":"2024-07-02T16:35:11.152Z","phase":"","brief_title":"Molecular-Guided Therapy for Childhood Cancer","source_id_and_acronym":"NCT02162732","lead_sponsor":"Giselle Sholler","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"],"overall_status":"Completed","enrollment":" Enrollment 186","initiation":"Initiation: 07/08/2014","start_date":" 07/08/2014","primary_txt":" Primary completion: 01/18/2024","primary_completion_date":" 01/18/2024","study_txt":" Completion: 01/18/2024","study_completion_date":" 01/18/2024","last_update_posted":"2024-04-05"},{"id":"0e0834be-0c1a-4cc9-89e5-a3e0950833c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04082520","created_at":"2021-02-11T16:54:03.522Z","updated_at":"2024-07-02T16:35:12.274Z","phase":"Phase 2","brief_title":"Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy","source_id_and_acronym":"NCT04082520","lead_sponsor":"Mayo Clinic","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 04/08/2020","start_date":" 04/08/2020","primary_txt":" Primary completion: 09/04/2024","primary_completion_date":" 09/04/2024","study_txt":" Completion: 09/04/2025","study_completion_date":" 09/04/2025","last_update_posted":"2024-03-29"},{"id":"f25984f7-928a-4db7-8a6a-64a803a17f17","acronym":"","url":"https://clinicaltrials.gov/study/NCT02933736","created_at":"2021-01-18T14:24:13.882Z","updated_at":"2025-02-25T15:53:32.297Z","phase":"Phase 1","brief_title":"Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients","source_id_and_acronym":"NCT02933736","lead_sponsor":"Nader Sanai","biomarkers":" CDKN2A • CCND1 • CDK4 • CDKN2B","pipe":" | ","alterations":" CDKN2A deletion","tags":["CDKN2A • CCND1 • CDK4 • CDKN2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-03-27"},{"id":"35e34361-ae0b-4c69-8d47-4171b1f9736a","acronym":"PROMENADE","url":"https://clinicaltrials.gov/study/NCT04997317","created_at":"2021-08-09T13:53:17.457Z","updated_at":"2024-07-02T16:35:15.190Z","phase":"Phase 1","brief_title":"Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide","source_id_and_acronym":"NCT04997317 - PROMENADE","lead_sponsor":"University Hospital, Basel, Switzerland","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SOMther (lutetium-177 DOTA satoreotide) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/21/2021","start_date":" 04/21/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-12"},{"id":"e4bb6ebb-d0a1-45a9-8623-25eb132314cd","acronym":"POPLAR-NF2","url":"https://clinicaltrials.gov/study/NCT05130866","created_at":"2023-08-24T11:08:27.986Z","updated_at":"2024-07-02T16:35:16.781Z","phase":"Phase 2/3","brief_title":"Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas","source_id_and_acronym":"NCT05130866 - POPLAR-NF2","lead_sponsor":"Recursion Pharmaceuticals Inc.","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e REC-2282"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 06/20/2022","start_date":" 06/20/2022","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-03-01"},{"id":"83a011cc-3ed7-453f-8d6a-4bfef59bfc3f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03583528","created_at":"2021-01-18T17:37:43.597Z","updated_at":"2024-07-02T16:35:22.583Z","phase":"","brief_title":"DOTATOC PET/CT for Imaging NET Patients","source_id_and_acronym":"NCT03583528","lead_sponsor":"British Columbia Cancer Agency","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive • SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR Expression"],"overall_status":"Recruiting","enrollment":" Enrollment 800","initiation":"Initiation: 07/11/2018","start_date":" 07/11/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-01-23"},{"id":"661ac498-4437-4c38-9e5f-f0a0399c4693","acronym":"","url":"https://clinicaltrials.gov/study/NCT00002965","created_at":"2021-01-17T22:49:15.449Z","updated_at":"2024-07-02T16:35:25.450Z","phase":"Phase 2","brief_title":"Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas","source_id_and_acronym":"NCT00002965","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IFNA1","pipe":"","alterations":" ","tags":["IFNA1"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 01/01/1997","start_date":" 01/01/1997","primary_txt":" Primary completion: 03/01/2003","primary_completion_date":" 03/01/2003","study_txt":" Completion: 03/01/2003","study_completion_date":" 03/01/2003","last_update_posted":"2023-12-22"},{"id":"425958b5-9602-4c65-963a-dd2cc9188c33","acronym":"","url":"https://clinicaltrials.gov/study/NCT04638478","created_at":"2021-01-19T20:38:09.392Z","updated_at":"2024-07-02T16:35:29.624Z","phase":"","brief_title":"PREselection of Patients at Risk for COgnitive DEcline After Radiotherapy Using Advanced MRI","source_id_and_acronym":"NCT04638478","lead_sponsor":"Maastricht Radiation Oncology","biomarkers":" KEAP1","pipe":"","alterations":" ","tags":["KEAP1"],"overall_status":"Recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 04/08/2021","start_date":" 04/08/2021","primary_txt":" Primary completion: 04/08/2025","primary_completion_date":" 04/08/2025","study_txt":" Completion: 04/08/2025","study_completion_date":" 04/08/2025","last_update_posted":"2023-11-10"},{"id":"a3b94b21-6e56-4be0-94d8-6e762635e9e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04792463","created_at":"2021-03-11T13:52:41.075Z","updated_at":"2024-07-02T16:35:31.698Z","phase":"","brief_title":"Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome","source_id_and_acronym":"NCT04792463","lead_sponsor":"Mohamed Abdel-Rahman","biomarkers":" BAP1","pipe":" | ","alterations":" BAP1 mutation","tags":["BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAP1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 03/03/2015","start_date":" 03/03/2015","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2023-10-25"},{"id":"0d0d15de-eb4a-4e35-9e1e-388c588b5f9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03971461","created_at":"2021-01-18T19:32:12.909Z","updated_at":"2024-07-02T16:35:40.851Z","phase":"Phase 2","brief_title":"Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma","source_id_and_acronym":"NCT03971461","lead_sponsor":"NYU Langone Health","biomarkers":" SSTR2","pipe":" | ","alterations":" SSTR2 expression • SSTR2 positive","tags":["SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression • SSTR2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 05/15/2019","start_date":" 05/15/2019","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2023-08-04"},{"id":"d0afaa59-8d9c-43d9-b962-8180fb565843","acronym":"","url":"https://clinicaltrials.gov/study/NCT03273712","created_at":"2021-02-11T16:53:25.958Z","updated_at":"2024-07-02T16:35:55.943Z","phase":"Phase 2","brief_title":"Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)","source_id_and_acronym":"NCT03273712","lead_sponsor":"University of Iowa","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 09/29/2017","start_date":" 09/29/2017","primary_txt":" Primary completion: 05/27/2020","primary_completion_date":" 05/27/2020","study_txt":" Completion: 05/27/2020","study_completion_date":" 05/27/2020","last_update_posted":"2023-02-09"},{"id":"7b27da0a-d639-42fd-a136-368d479a1f3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02831257","created_at":"2021-01-18T13:53:02.982Z","updated_at":"2025-02-25T15:07:09.140Z","phase":"Phase 2","brief_title":"AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas","source_id_and_acronym":"NCT02831257","lead_sponsor":"Massachusetts General Hospital","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vistusertib (AZD2014)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 08/31/2016","start_date":" 08/31/2016","primary_txt":" Primary completion: 05/31/2019","primary_completion_date":" 05/31/2019","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2022-06-13"},{"id":"e2f4220b-368a-4d6f-ba44-2b13c683e1d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01125046","created_at":"2021-01-23T00:52:22.369Z","updated_at":"2024-07-02T16:36:35.684Z","phase":"Phase 2","brief_title":"Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas","source_id_and_acronym":"NCT01125046","lead_sponsor":"Northwestern University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • VEGFA expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • VEGFA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 06/17/2010","start_date":" 06/17/2010","primary_txt":" Primary completion: 03/10/2014","primary_completion_date":" 03/10/2014","study_txt":" Completion: 12/31/2018","study_completion_date":" 12/31/2018","last_update_posted":"2021-01-22"},{"id":"d98ff5d6-925d-43e6-bcc2-7274e5cffa2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03936426","created_at":"2021-02-11T16:53:54.174Z","updated_at":"2024-07-02T16:36:45.846Z","phase":"Phase 1/2","brief_title":"Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™","source_id_and_acronym":"NCT03936426","lead_sponsor":"Clarity Pharmaceuticals Ltd","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Sartate (67Cu MeCOSar octreotate)"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 07/09/2018","start_date":" 07/09/2018","primary_txt":" Primary completion: 09/19/2019","primary_completion_date":" 09/19/2019","study_txt":" Completion: 09/19/2019","study_completion_date":" 09/19/2019","last_update_posted":"2020-04-20"},{"id":"d03a5d8d-542b-4e6b-a003-02c4910b01b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03648034","created_at":"2021-01-18T17:54:23.929Z","updated_at":"2024-07-02T16:36:46.648Z","phase":"","brief_title":"Effects of Scalp Nerve Block With Ropivacaine on Postoperative Recovery Quality","source_id_and_acronym":"NCT03648034","lead_sponsor":"RenJi Hospital","biomarkers":" IL6 • TNFA • IL1B","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL1B"],"overall_status":"Completed","enrollment":" Enrollment 144","initiation":"Initiation: 09/18/2018","start_date":" 09/18/2018","primary_txt":" Primary completion: 09/30/2019","primary_completion_date":" 09/30/2019","study_txt":" Completion: 11/30/2019","study_completion_date":" 11/30/2019","last_update_posted":"2020-04-06"}]